Sukh Makhnoon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sukh Makhnoon has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
Susan K. Peterson
Department of Behavioral Science The University of Texas MD Anderson Cancer Center Houston Texas USA
9 shared publicationsBanu Arun
Clinical Cancer Genetics, UT MD Anderson Cancer Center, Houston, TX
6 shared publications- Banu K. Arun
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
5 shared publications - Sanjay Shete
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
5 shared publications Sara Pirzadeh-Miller
4 shared publicationsTiwatope Ibidapo
4 shared publications
Latest Publications
Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience
Background: Clinical trials add to the financial burden of cancer care. To expand equitable access to trials, from 2006 to 2024 the Lazarex Cancer Foundation reimbursed nonmedical expenses related to therapeutic cancer clinical trial participation. Methods: Eligible patients were enrolled in a cancer treatment trial and had a household income of ≤700% of the federal poverty level. Expense reimbursement occurred at 50%, 75%, and 100% according to income level. This study analyzed the type, timing, and amounts (in 2024 dollars) of reimbursed expenses for trial participants. Associations between patient/trial characteristics, reimbursed amounts, and distance traveled were evaluated via t ‐tests, analysis of variance, and multivariate linear regression. Results: Overall, 2826 individuals (64% non‐Hispanic White, 97% with health insurance, with a median household income of $50,948) received at least one reimbursement. Median total per‐patient reimbursement was $2128, median trial participation duration was 4.3 months, and monthly reimbursed amounts declined substantially throughout trial participation. Types of reimbursement varied by patient income: internet, ground transportation, and child/elder care were more common at lower income levels, whereas lodging and airfare were more common for higher incomes. In multivariate analysis, monthly reimbursed amount was greater among middle‐tier household income quartiles ( p = .003), greater distance to trial site ( p < .001), and phase 1 trials ( p = .001). The proportion of patients participating across income levels remained stable over time. Conclusions: Reimbursement needs during cancer clinical trial participation are dynamic and closely tied to both socioeconomic status and logistical burden, particularly travel distance and trial intensity. Financial support for these expenses may enhance trial accessibility and retention.
Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience
Background: Clinical trials add to the financial burden of cancer care. To expand equitable access to trials, from 2006 to 2024 the Lazarex Cancer Foundation reimbursed nonmedical expenses related to therapeutic cancer clinical trial participation. Methods: Eligible patients were enrolled in a cancer treatment trial and had a household income of ≤700% of the federal poverty level. Expense reimbursement occurred at 50%, 75%, and 100% according to income level. This study analyzed the type, timing, and amounts (in 2024 dollars) of reimbursed expenses for trial participants. Associations between patient/trial characteristics, reimbursed amounts, and distance traveled were evaluated via t ‐tests, analysis of variance, and multivariate linear regression. Results: Overall, 2826 individuals (64% non‐Hispanic White, 97% with health insurance, with a median household income of $50,948) received at least one reimbursement. Median total per‐patient reimbursement was $2128, median trial participation duration was 4.3 months, and monthly reimbursed amounts declined substantially throughout trial participation. Types of reimbursement varied by patient income: internet, ground transportation, and child/elder care were more common at lower income levels, whereas lodging and airfare were more common for higher incomes. In multivariate analysis, monthly reimbursed amount was greater among middle‐tier household income quartiles ( p = .003), greater distance to trial site ( p < .001), and phase 1 trials ( p = .001). The proportion of patients participating across income levels remained stable over time. Conclusions: Reimbursement needs during cancer clinical trial participation are dynamic and closely tied to both socioeconomic status and logistical burden, particularly travel distance and trial intensity. Financial support for these expenses may enhance trial accessibility and retention.
- 1 October 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (12)
CHARGE free cascade genetic testing: Effectiveness and implementation outcomes from a hybrid type I feasibility trial
- 1 October 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (12)
CHARGE free cascade genetic testing: Effectiveness and implementation outcomes from a hybrid type I feasibility trial
- Open Access
- 15 April 2026
- Published by Springer Nature in BMC Primary Care
- Vol. 27 (1)
Primary care stakeholder perspectives on clinical implementation of patient-reported hereditary cancer risk-assessment
Most individuals at increased risk of hereditary cancers are unaware of their risk status, in part due to the suboptimal implementation of evidence-based h
- 15 April 2026
- Published by Springer Nature in BMC Primary Care
- Vol. 27 (1)
Open AccessPrimary care stakeholder perspectives on clinical implementation of patient-reported hereditary cancer risk-assessment
Most individuals at increased risk of hereditary cancers are unaware of their risk status, in part due to the suboptimal implementation of evidence-based h
- Open Access
- 6 August 2025
- Published by Springer Nature in BMC Primary Care
- Vol. 26 (1) , 1-8
Adaptation and pilot implementation of a hereditary cancer risk-assessment tool for primary care
Background: Family history-based risk assessment for hereditary breast and ovarian cancer is guideline-recommended but clinical implementation remains limited. This is likely, in part, because it adds to the limited time primary care providers (PCPs) have to implement all guideline-recommended care. Methods: We adapted Family History Screening 7 (or FHS7), designed for administration by a PCP, for self-report by primary care patients. We used the Framework for Reporting Adaptation and Modifications to Evidence-based Implementation Strategies (FRAME) to guide the modifications. We conducted a pilot feasibility study of hereditary prevention program using the adapted risk-assessment tool and report results from the first year of the program (February 2023-March 2024). Results: Feedback from clinical stakeholders and our literature review revealed that, while hereditary cancer risk assessment was a priority for the primary care setting, implementation by PCPs was not feasible. We therefore adapted FHS7 for patient self-report by separating double-barreled items and eliminating jargon, resulting in nine items– six with binary (yes/no) and three with numeric responses. Outcomes from pilot implementation of the adapted FHS7 (n=4,355) showed high completion rate (77% completed all items), with greater completion via MyChart than in-person (87% vs. 13%), and higher non-response for the three items with numeric responses compared to the six with binary responses. Overall, positivity rate of the adapted FHS7 was 36%. Conclusion: This paper describes our team’s process of adapting the FHS7 questionnaire to retain the core function (evaluating specific family history of cancer information) while adapting to fit the clinical context. Preliminary implementation data suggest high completion rate in the primary care setting.
- 6 August 2025
- Published by Springer Nature in BMC Primary Care
- Vol. 26 (1) , 1-8
Open AccessAdaptation and pilot implementation of a hereditary cancer risk-assessment tool for primary care
Background: Family history-based risk assessment for hereditary breast and ovarian cancer is guideline-recommended but clinical implementation remains limited. This is likely, in part, because it adds to the limited time primary care providers (PCPs) have to implement all guideline-recommended care. Methods: We adapted Family History Screening 7 (or FHS7), designed for administration by a PCP, for self-report by primary care patients. We used the Framework for Reporting Adaptation and Modifications to Evidence-based Implementation Strategies (FRAME) to guide the modifications. We conducted a pilot feasibility study of hereditary prevention program using the adapted risk-assessment tool and report results from the first year of the program (February 2023-March 2024). Results: Feedback from clinical stakeholders and our literature review revealed that, while hereditary cancer risk assessment was a priority for the primary care setting, implementation by PCPs was not feasible. We therefore adapted FHS7 for patient self-report by separating double-barreled items and eliminating jargon, resulting in nine items– six with binary (yes/no) and three with numeric responses. Outcomes from pilot implementation of the adapted FHS7 (n=4,355) showed high completion rate (77% completed all items), with greater completion via MyChart than in-person (87% vs. 13%), and higher non-response for the three items with numeric responses compared to the six with binary responses. Overall, positivity rate of the adapted FHS7 was 36%. Conclusion: This paper describes our team’s process of adapting the FHS7 questionnaire to retain the core function (evaluating specific family history of cancer information) while adapting to fit the clinical context. Preliminary implementation data suggest high completion rate in the primary care setting.
- Open Access
- 2 August 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (15) , e71125
Implementation of a Patient Navigation Program to Support Representative Participation in Cancer Clinical Trials
Background: Achieving adequate, timely, and diverse trial enrollment remains a major challenge in clinical research. Insufficiently diverse patient representation compromises the generalizability of clinical trial findings and remains a persistent issue in oncology. Navigation services may help patients learn about clinical trials, identify and overcome barriers, and progress through the care pathway to trial enrollment and retention. Methods: We implemented a patient navigation program to support diverse enrollment and retention of patients in cancer clinical trials; the proximal outcomes were receipt of financial navigation and trial interest. The study was conducted from July 2023 to July 2024 at two demographically diverse health care settings: a university‐based tertiary healthcare system and an integrated safety‐net healthcare system. Evaluation was guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework and incorporated programmatic data, structured surveys of patients and staff, and qualitative patient interviews. Results: The program navigated 429 oncology patients (52% female, 28% Hispanic/Latino (HL), and 16% non‐HL Black). Compared to the underlying patient population of the clinical settings, program participants were more likely to be Hispanic (31% vs. 21%; p < 0.01), female (52% vs. 48%; p = 0.01) and from a minority race (30% vs. 24%, p ≤ 0.01). Within the population who were successfully contacted, 325 of 408 (92%) patients already enrolled in a trial received financial navigation to help with trial retention. Among the remaining 83 patients not enrolled in a cancer clinical trial at the time of referral, 39 (47%) expressed interest in participating in a clinical trial in thefuture. Conclusion: A patient navigation program to influence enrollment and retention of diverse patients into trials was feasible to implement, highly acceptable to patients, and reached a priority population of patients generally underrepresented in cancer clinical trials. Further research into the effect of navigation on trial enrollment and retention is warranted.
- 2 August 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (15) , e71125
Open AccessImplementation of a Patient Navigation Program to Support Representative Participation in Cancer Clinical Trials
Background: Achieving adequate, timely, and diverse trial enrollment remains a major challenge in clinical research. Insufficiently diverse patient representation compromises the generalizability of clinical trial findings and remains a persistent issue in oncology. Navigation services may help patients learn about clinical trials, identify and overcome barriers, and progress through the care pathway to trial enrollment and retention. Methods: We implemented a patient navigation program to support diverse enrollment and retention of patients in cancer clinical trials; the proximal outcomes were receipt of financial navigation and trial interest. The study was conducted from July 2023 to July 2024 at two demographically diverse health care settings: a university‐based tertiary healthcare system and an integrated safety‐net healthcare system. Evaluation was guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework and incorporated programmatic data, structured surveys of patients and staff, and qualitative patient interviews. Results: The program navigated 429 oncology patients (52% female, 28% Hispanic/Latino (HL), and 16% non‐HL Black). Compared to the underlying patient population of the clinical settings, program participants were more likely to be Hispanic (31% vs. 21%; p < 0.01), female (52% vs. 48%; p = 0.01) and from a minority race (30% vs. 24%, p ≤ 0.01). Within the population who were successfully contacted, 325 of 408 (92%) patients already enrolled in a trial received financial navigation to help with trial retention. Among the remaining 83 patients not enrolled in a cancer clinical trial at the time of referral, 39 (47%) expressed interest in participating in a clinical trial in thefuture. Conclusion: A patient navigation program to influence enrollment and retention of diverse patients into trials was feasible to implement, highly acceptable to patients, and reached a priority population of patients generally underrepresented in cancer clinical trials. Further research into the effect of navigation on trial enrollment and retention is warranted.
- Open Access
- 21 July 2025
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 13 (7) , e70123
Electronic Patient Portals as a Modality for Returning Reclassified Genetic Test Results
Background: Most reclassified genetic test results are clinically inactionable and burdensome for healthcare providers to return to patients. The feasibility of using electronic patient portals (e.g., MyChart) to return reclassified results remains unclear.Methods: Patient and provider initiated MyChart actions were obtained from MyChart data and matched to patient demographic and clinical information using unique patient medical record numbers. Data on who (patient or provider) sent and read these messages and when (date and time) were collected for clinically actionable and inactionable reclassifications.Results: Among 801 patients with 828 reclassified variants in cancer susceptibility genes, 551 had an active MyChart account at the time of reclassification. Patients with active MyChart accounts were less likely to be Hispanic (p < 0.001) compared to other ethnic groups. Of these, 302 (55%) were notified about 308 reclassified results (307 inactionable and 1 actionable) via MyChart messages, and 80% (244/302) read the message within a median time of 3.6 h.Conclusion: We find that it is feasible to return reclassified results via electronic patient portals for most patients, but alternative modalities are still necessary. Unidirectional, low‐touch modalities of recontact can be used to efficiently return the increasing number of inactionable reclassified results.
- 21 July 2025
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 13 (7) , e70123
Open AccessElectronic Patient Portals as a Modality for Returning Reclassified Genetic Test Results
Background: Most reclassified genetic test results are clinically inactionable and burdensome for healthcare providers to return to patients. The feasibility of using electronic patient portals (e.g., MyChart) to return reclassified results remains unclear.Methods: Patient and provider initiated MyChart actions were obtained from MyChart data and matched to patient demographic and clinical information using unique patient medical record numbers. Data on who (patient or provider) sent and read these messages and when (date and time) were collected for clinically actionable and inactionable reclassifications.Results: Among 801 patients with 828 reclassified variants in cancer susceptibility genes, 551 had an active MyChart account at the time of reclassification. Patients with active MyChart accounts were less likely to be Hispanic (p < 0.001) compared to other ethnic groups. Of these, 302 (55%) were notified about 308 reclassified results (307 inactionable and 1 actionable) via MyChart messages, and 80% (244/302) read the message within a median time of 3.6 h.Conclusion: We find that it is feasible to return reclassified results via electronic patient portals for most patients, but alternative modalities are still necessary. Unidirectional, low‐touch modalities of recontact can be used to efficiently return the increasing number of inactionable reclassified results.
- 5 June 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 155, 107979
Choice architecture in cascade genetic testing (CHARGE study) for hereditary cancer: Design of a hybrid type I randomized feasibility trial
- 5 June 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 155, 107979
Choice architecture in cascade genetic testing (CHARGE study) for hereditary cancer: Design of a hybrid type I randomized feasibility trial
- Open Access
- 11 July 2024
- Published by Elsevier in Genetics in Medicine Open
- Vol. 2, 101867
Variant reclassification and recontact research: A scoping review
- 11 July 2024
- Published by Elsevier in Genetics in Medicine Open
- Vol. 2, 101867
Open AccessVariant reclassification and recontact research: A scoping review
- Open Access
What do cancer genetic providers want us to know about variant reclassification and recontact that we are not asking? A thematic analysis of open‐ended survey responses
Background: Accurate variant classification and relaying reclassified results to patients is critical for hereditary cancer care delivery. Over a 5‐ to 10‐year period, 6%–15% of variants undergo reclassification. As the frequency of reclassifications increases, the issue of whether, how, when, and which providers should recontact patients becomes important but remains contentious.Methods: The authors used inductive thematic analysis to analyze open‐ended comments offered by oncologists and genetic counselors (GCs) from a large national survey.Results: Of the 634 oncologists and cancer GCs, 126 (20%) offered substantive free‐text comments. Four thematic areas emerged: 1) ambiguity over professional responsibility to recontact, 2) logistical challenges with recontact, 3) importance of inter‐institutional communication, and 4) suggested solutions. Some oncologists felt that laboratories, not them, are responsible for recontact; others believed that ordering providers/GCs were responsible; GCs readily acknowledged their own responsibility in recontact but added important caveats. Besides the lack of up‐to‐date patient contact information, providers raised unique challenges with recontact: financial instability of laboratories, lack of clinical resources, contacting family members, and accumulating burden of reclassifications. There were numerous calls for developing practice guidelines on prioritizing variants for recontact and discussion on whether duty for recontact may be fulfilled via unidirectional, low touch modalities. Potential solutions to recontact including national databases and patient facing databases were discussed.Conclusions: The authors confirm previous themes of stakeholder opinions and add previously unreported contextual details to qualify those themes. Clarifying provider responsibilities through professional guidelines for reclassification and recontact addressing the subthemes identified here will better serve all constituencies.
Open AccessWhat do cancer genetic providers want us to know about variant reclassification and recontact that we are not asking? A thematic analysis of open‐ended survey responses
Background: Accurate variant classification and relaying reclassified results to patients is critical for hereditary cancer care delivery. Over a 5‐ to 10‐year period, 6%–15% of variants undergo reclassification. As the frequency of reclassifications increases, the issue of whether, how, when, and which providers should recontact patients becomes important but remains contentious.Methods: The authors used inductive thematic analysis to analyze open‐ended comments offered by oncologists and genetic counselors (GCs) from a large national survey.Results: Of the 634 oncologists and cancer GCs, 126 (20%) offered substantive free‐text comments. Four thematic areas emerged: 1) ambiguity over professional responsibility to recontact, 2) logistical challenges with recontact, 3) importance of inter‐institutional communication, and 4) suggested solutions. Some oncologists felt that laboratories, not them, are responsible for recontact; others believed that ordering providers/GCs were responsible; GCs readily acknowledged their own responsibility in recontact but added important caveats. Besides the lack of up‐to‐date patient contact information, providers raised unique challenges with recontact: financial instability of laboratories, lack of clinical resources, contacting family members, and accumulating burden of reclassifications. There were numerous calls for developing practice guidelines on prioritizing variants for recontact and discussion on whether duty for recontact may be fulfilled via unidirectional, low touch modalities. Potential solutions to recontact including national databases and patient facing databases were discussed.Conclusions: The authors confirm previous themes of stakeholder opinions and add previously unreported contextual details to qualify those themes. Clarifying provider responsibilities through professional guidelines for reclassification and recontact addressing the subthemes identified here will better serve all constituencies.
- Open Access
- 8 April 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 39, 101292
Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program
- 8 April 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 39, 101292
Open AccessTransferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program